Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - ROCKWELL MEDICAL, INC. | d480572dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 4, 2013
ROCKWELL MEDICAL, INC.
(Exact name of registrant as specified in its charter)
| Michigan | 000-23661 | 38-3317208 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 30142 Wixom Road, Wixom, Michigan |
48393 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (248) 960-9009
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On February 4, 2013, Rockwell Medical, Inc. (the “Company”) issued a press release announcing top-line results from the PRIME clinical study of Soluble Ferric Pyrophosphate (“SFP”), its investigational iron-delivery drug currently in Phase 3 clinical studies for the treatment of iron deficiency in hemodialysis patients. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits. |
| Exhibit 99.1 | Press Release, dated February 4, 2013 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ROCKWELL MEDICAL, INC. | ||||||
| Date: February 4, 2013 |
By: |
/s/ Thomas E. Klema | ||||
| Thomas E. Klema | ||||||
| Its: Chief Financial Officer | ||||||
3